Abstract
The leucine-rich and immunoglobulin-like domains (LRIG) gene family contains LRIG1, 2 and 3. LRIG1 is a negative regulator of EGFR, but little is known about the function of LRIG2. To determine the role of LRIG2 in the progression of glioma, we performed RNA interference-mediated knockdown of LRIG2 in a human glioma cell line (GL15). Downregulation of LRIG2 expression resulted in: rapid EGF-mediated loss of EGFR; decreased proliferation; G(0)/G(1) arrest; increased spontaneous apoptosis; enhanced cell adhesion and increased invasion capability of GL15 cells in vitro. These findings indicate that LRIG2 possesses distinct functions compared with LRIG1 and validate the attractiveness of LRIG2 as a target in glioma therapy.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Apoptosis / genetics
-
Cell Adhesion / genetics
-
Cell Cycle / genetics
-
Cell Line, Tumor
-
Central Nervous System Neoplasms / genetics*
-
Central Nervous System Neoplasms / pathology
-
Down-Regulation
-
Epidermal Growth Factor / pharmacology
-
ErbB Receptors / biosynthesis
-
ErbB Receptors / genetics
-
Glioblastoma / genetics*
-
Glioblastoma / pathology
-
Humans
-
Membrane Glycoproteins / biosynthesis
-
Membrane Glycoproteins / deficiency
-
Membrane Glycoproteins / genetics*
-
RNA Interference
-
RNA, Neoplasm / genetics
-
RNA, Small Interfering / genetics*
-
Transfection
Substances
-
LRIG2 protein, human
-
Membrane Glycoproteins
-
RNA, Neoplasm
-
RNA, Small Interfering
-
Epidermal Growth Factor
-
ErbB Receptors